Posts by: Forest Ray PhD

Forest Ray PhD

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

February 18, 2021February 18, 2021

Erleada-Zytiga Combo Delays Progression in mCRPC Patients, Phase 3 Trial Reports

News

Combining Erleada (apalutamide) and Zytiga (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC) significantly extends the time patients live without signs of disease worsening, compared with Zytiga alone, Janssen announced ... Read more

February 2, 2021February 2, 2021

NBA Teams Join Efforts to Raise Money and Awareness

News

The Prostate Cancer Foundation (PCF) and several NBA teams are joining efforts to raise money and awareness for prostate cancer research throughout February. Various national basketball teams, including the Atlanta ... Read more

December 8, 2020December 8, 2020

FDA Puts RV001 on Fast Track for Treating Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has granted fast track status to RV001, RhoVac‘s investigational therapy for prostate cancer, the company announced. Fast track designation helps speed the approval ... Read more

December 3, 2020December 3, 2020

FDA Approves First PSMA-targeted PET Imaging Agent for Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) as a positron emission tomography or PET imaging agent for men with prostate cancer. The ... Read more

November 24, 2020November 24, 2020

PCF Helps Fund 2 Centers of Excellence to Treat Veterans With Prostate Cancer

News

The Prostate Cancer Foundation (PCF) has committed $5 million to support the launch of two new Centers of Excellence that will provide precision medicine treatments to veterans with prostate cancer. ... Read more

October 8, 2020October 8, 2020

Veru Completes Enrollment for Second Part of Phase 1/2 VERU-111 Trial

News

Veru has completed enrollment for the second portion of a Phase 1/2 study of VERU-111, its investigational therapy for men with metastatic castration-resistant prostate cancer (mCRPC) who failed to respond ... Read more

October 6, 2020October 6, 2020

Lantheus Seeks FDA Approval of PyL Prostate Cancer Imaging Agent

News

Lantheus Holdings has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of PyL, an investigational imaging agent used to locate prostate cancer lesions. The new ... Read more

August 25, 2020August 25, 2020

Tolmar Affirms Full Supply of Eligard for Palliative Treatment of Prostate Cancer

News

Tolmar Pharmaceuticals maintains a complete inventory of Eligard (leuprolide acetate), its therapy for advanced prostate cancer, and had increased production in response to reports of shortages of other leuprolide acetate ... Read more

June 30, 2020June 30, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

News, syndicated

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for marketed ... Read more

March 2, 2020March 2, 2020

Statins, Metformin May Extend Survival in High-risk Prostate Cancer, Large Study Suggests

News

The use of statins — cholesterol-lowering agents to treat cardiovascular disease — alone or in combination with the diabetes treatment metformin, may increase survival in men with high-risk prostate cancer, ... Read more